Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780403 | 0.84 | KDM4E (0.46) | EPHX1LOXL2TAAR1SLC6A2NOS3 | |
| SCHEMBL14032489 | 0.84 | TAAR1 (0.59) | EPHX1TAAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL12118748 | 0.84 | EPHX1 (0.50) | EPHX1TAAR1ALOX5 | |
| SCHEMBL23643109 | 0.84 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SMN1; SMN2ALOX5 | |
| SCHEMBL16017643 | 0.84 | TBXAS1 (0.51) | LOXL2TAAR1SLC6A2KDM4ESMN1; SMN2 | |
| SCHEMBL28052529 | 0.84 | TBXAS1 (0.51) | LOXL2TAAR1SLC6A2KDM4ESMN1; SMN2 | |
| SCHEMBL934530 | 0.84 | TAAR1 (0.59) | EPHX1TAAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL22593510 | 0.84 | EPHX1 (0.50) | EPHX1TAAR1ALOX5 | |
| SCHEMBL22937469 | 0.84 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2ALOX5 | |
| SCHEMBL13248740 | 0.84 | TAAR1 (0.59) | EPHX1TAAR1SLC6A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | EPHX1 988/4885LOXL2 2970/4885TAAR1 3617/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | EPHX1 988/4885LOXL2 2970/4885TAAR1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.